Health
Genethon develops gene therapy for treating Duchenne muscular dystrophy – News-Medical.net
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM,…
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004.
This trial’s goal is to assess the safety and efficacy of an innovative gene therapy designed at Genethon, combining an AAV-type viral vector…
-
Noosa News22 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
General24 hours agoEV buses join Perth’s wider suburban network, ‘milestone’ for diesel phase-out
-
Noosa News22 hours agoWoman loses arm in lion attack at Darling Downs Zoo in Queensland
-
General18 hours agoJordan Thompson retires from Wimbledon round-of-16 match with American Taylor Fritz